These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10412728)

  • 1. Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease.
    Attman PO; Alaupovic P; Samuelsson O
    Kidney Int Suppl; 1999 Jul; 71():S14-7. PubMed ID: 10412728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression of renal failure: role of apolipoprotein B-containing lipoproteins.
    Attman PO; Samuelsson O; Alaupovic P
    Kidney Int Suppl; 1997 Dec; 63():S98-101. PubMed ID: 9407433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and classification of dyslipidemia in renal disease.
    Attman PO; Samuelsson O; Alaupovic P
    Blood Purif; 1996; 14(1):49-57. PubMed ID: 8718566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency.
    Samuelsson O; Attman PO; Knight-Gibson C; Larsson R; Mulec H; Weiss L; Alaupovic P
    J Am Soc Nephrol; 1998 Aug; 9(8):1482-8. PubMed ID: 9697671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease.
    Samuelsson O; Attman PO; Knight-Gibson C; Kron B; Larsson R; Mulec H; Weiss L; Alaupovic P
    Nephron; 1997; 75(3):286-94. PubMed ID: 9069450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein metabolism and renal failure.
    Attman PO; Samuelsson O; Alaupovic P
    Am J Kidney Dis; 1993 Jun; 21(6):573-92. PubMed ID: 8503411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis.
    Attman PO; Samuelsson OG; Moberly J; Johansson AC; Ljungman S; Weiss LG; Knight-Gibson C; Alaupovic P
    Kidney Int; 1999 Apr; 55(4):1536-42. PubMed ID: 10201020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atherogenicity of triglyceride-rich lipoproteins.
    Krauss RM
    Am J Cardiol; 1998 Feb; 81(4A):13B-17B. PubMed ID: 9526808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lipid metabolism abnormalities in Chronic Kidney Disease].
    Bianchi S; Baronti A; Cominotto R; Bigazzi R
    G Ital Nefrol; 2016 Malattie Metaboliche e Rene; 33(S68):. PubMed ID: 27960010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients.
    Cassader M; Gambino R; Musso G; Depetris N; Mecca F; Cavallo-Perin P; Pacini G; Rizzetto M; Pagano G
    Lipids; 2001 Oct; 36(10):1117-24. PubMed ID: 11768156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of decreasing renal function on lipoprotein profiles.
    Attman PO; Samuelsson O; Alaupovic P
    Nephrol Dial Transplant; 2011 Aug; 26(8):2572-5. PubMed ID: 21220758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ELISA quantitation of apolipoproteins in plasma lipoprotein fractions: ApoE in ApoB-containing lipoproteins (Lp B:E) and ApoB in ApoE-containing lipoproteins (Lp E:B).
    Yang CY; Xie YH; Yang M; Quion JA; Gotto AM
    J Protein Chem; 1995 Oct; 14(7):503-9. PubMed ID: 8561846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and partial characterization of discrete apolipoprotein B containing lipoprotein particles produced by human hepatoma cell line HepG2.
    Dashti N; Alaupovic P; Knight-Gibson C; Koren E
    Biochemistry; 1987 Jul; 26(15):4837-46. PubMed ID: 2822101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein-B-containing lipoproteins and the progression of renal insufficiency.
    Samuelsson O; Aurell M; Knight-Gibson C; Alaupovic P; Attman PO
    Nephron; 1993; 63(3):279-85. PubMed ID: 8446264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Determination of potentially atherogenic triglyceride-rich lipoprotein particles].
    Alaupovic P; Blankenhorn DH
    Klin Wochenschr; 1990; 68 Suppl 22():38-42. PubMed ID: 2087077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.
    Vaziri ND
    Kidney Int; 2016 Jul; 90(1):41-52. PubMed ID: 27165836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.
    Hodis HN; Mack WJ; Azen SP; Alaupovic P; Pogoda JM; LaBree L; Hemphill LC; Kramsch DM; Blankenhorn DH
    Circulation; 1994 Jul; 90(1):42-9. PubMed ID: 8026027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ApoA- and apoB-containing lipoproteins and Lp(a) concentration in non-dialyzed patients with chronic renal failure.
    Kimak E; Solski J
    Ren Fail; 2002 Jul; 24(4):485-92. PubMed ID: 12212828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.